{"success":true,"data":{"pressRelease":{"id":"124626","rtpr_id":"nGNX2P6HGj","ticker":"IPN","exchange":"Euronext Paris","all_tickers":["IPN"],"title":"Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline","author":"Globe Newswire","published_at":"2026-08-21T05:00:00.359Z","article_body":"PARIS, FRANCE, 21 AUGUST 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced\ntoday it has completed the acquisition of Kartos Therapeutics, a\nclinical-stage biopharmaceutical company adding late-stage MDM2 inhibitor\nnavtemadlin in Phase III clinical development in myelofibrosis.\n\nAbout navtemadlin\nNavtemadlin is an investigational oral MDM2 inhibitor being developed as an\nadd-on therapy to ruxolitinib for patients with myelofibrosis who have a\nsuboptimal response to ruxolitinib. The Phase III POIESIS study is evaluating\nwhether the addition of navtemadlin could improve clinical outcomes compared\nwith ruxolitinib alone in this patient population. Early clinical data\ndemonstrate navtemadlin has the potential to transform suboptimal responses to\nstandard of care ruxolitinib into clinically meaningful responses in patients\nwith intermediate and high risk TP53wt myelofibrosis, to provide both enhanced\nclinical outcomes and potential disease-modifying benefit.\n\nAbout myelofibrosis\nMyelofibrosis is a myeloproliferative neoplasm, frequently linked to\nalterations in the JAK/STAT pathway, in which patients develop bone marrow\nfibrosis due to the abnormal proliferation of hematopoietic stem cells and\nsecretion of fibrogenic cytokines. As marrow function declines, blood\nproduction shifts to other organs, most often the spleen, leading to\nsplenomegaly. Myelofibrosis is characterized by bone marrow failure, fibrosis,\nsplenomegaly and a high symptom burden that can significantly affect quality\nof life, including fatigue, night sweats and other progressive symptoms. It\nalso carries a risk of transformation to acute myeloid leukemia. The median\nage at diagnosis is approximately 67–69 years and the condition affects\naround 1.5 per 100,000 people in the U.S. and Europe. Approximately 75–89%\nof patients are intermediate- or high-risk at diagnosis and more than 95% are\nTP53wt. Ruxolitinib, a JAK inhibitor, is the first-line standard of care;\nhowever, it is estimated that a significant proportion of patients have an\ninitial suboptimal response and approximately 50%-75% discontinue treatment\nafter three years. Median overall survival is typically one to two years after\ntreatment discontinuation, underscoring the need for new strategies that can\nincrease the number of patients that can achieve optimal clinical outcomes.\n\nAbout Ipsen\nWe are a global biopharmaceutical company with a focus on bringing\ntransformative medicines to patients in three therapeutic areas: Oncology,\nRare Disease and Neuroscience. Our pipeline is fueled by internal and external\ninnovation and supported by nearly 100 years of development experience and\nglobal hubs in the U.S., France and the U.K. Our teams in more than 40\ncountries and our partnerships around the world enable us to bring medicines\nto patients in more than 100 countries.\n\nIpsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored\nLevel I American Depositary Receipt program (ADR: IPSEY). For more\ninformation, visit ipsen.com\n(https://www.globenewswire.com/Tracker?data=BbAZ2BLSbvGq6xmtVoi1-iGZTycFlW2vubdYjMJ4Bfl7W3zruifxm8x1raxkR2Ko-4GUVOY8qt1OWiWlqPJqtA==).\n\n Ipsen Contacts                                                 \n Investors                                                      \n Henry Wheeler   henry.wheeler@ipsen.com     +33 7 66 47 11 49  \n Khalid Deojee   khalid.deojee@ipsen.com     +33 6 66 01 95 26  \n                                                                \n Media                                                          \n Sally Bain      sally.bain@ipsen.com        +1 857 320 0517    \n Anne Liontas    anne.liontas.ext@ipsen.com  +33 7 67 34 72 96  \n                                                                \n\nDisclaimers and/or forward-looking statements\nThe forward-looking statements, objectives and targets contained herein are\nbased on Ipsen’s management strategy, current views and assumptions. Such\nstatements involve known and unknown risks and uncertainties that may cause\nactual results, performance or events to differ materially from those\nanticipated herein. All of the above risks could affect Ipsen’s future\nability to achieve its financial targets, which were set assuming reasonable\nmacroeconomic conditions based on the information available today. Use of the\nwords ‘believes’, ‘anticipates’ and ‘expects’ and similar\nexpressions are intended to identify forward-looking statements, including\nIpsen’s expectations regarding future events, including regulatory filings\nand determinations. Moreover, the targets described in this document were\nprepared without taking into account external-growth assumptions and potential\nfuture acquisitions, which may alter these parameters. These objectives are\nbased on data and assumptions regarded as reasonable by Ipsen. These targets\ndepend on conditions or facts likely to happen in the future, and not\nexclusively on historical data. Actual results may depart significantly from\nthese targets given the occurrence of certain risks and uncertainties, notably\nthe fact that a promising medicine in early development phase or clinical\ntrial may end up never being launched on the market or reaching its commercial\ntargets, notably for regulatory or competition reasons. Ipsen must face or\nmight face competition from generic medicine that might translate into a loss\nof market share. Furthermore, the research and development process involves\nseveral stages each of which involves the substantial risk that Ipsen may fail\nto achieve its objectives and be forced to abandon its efforts with regards to\na medicine in which it has invested significant sums. Therefore, Ipsen cannot\nbe certain that favorable results obtained during preclinical trials will be\nconfirmed subsequently during clinical trials, or that the results of clinical\ntrials will be sufficient to demonstrate the safe and effective nature of the\nmedicine concerned. There can be no guarantees a medicine will receive the\nnecessary regulatory approvals or that the medicine will prove to be\ncommercially successful. If underlying assumptions prove inaccurate or risks\nor uncertainties materialize, actual results may differ materially from those\nset forth in the forward-looking statements. Other risks and uncertainties\ninclude but are not limited to, general industry conditions and competition;\ngeneral economic factors, including interest rate and currency exchange rate\nfluctuations; the impact of pharmaceutical industry regulation and healthcare\nlegislation and risks arising from unexpected regulatory or political changes\nsuch as changes in tax regulation and regulations on trade and tariffs, such\nas protectionist measures, especially in the United States; global trends\ntoward healthcare cost containment; technological advances, new medicine and\npatents attained by competitors; challenges inherent in new-medicine\ndevelopment, including obtaining regulatory approval; Ipsen’s ability to\naccurately predict future market conditions; manufacturing difficulties or\ndelays; financial instability of international economies and sovereign risk;\ndependence on the effectiveness of Ipsen’s patents and other protections for\ninnovative medicines; and the exposure to litigation, including patent\nlitigation, and/or regulatory actions. Ipsen also depends on third parties to\ndevelop and market some of its medicines which could potentially generate\nsubstantial royalties; these partners could behave in such ways which could\ncause damage to Ipsen’s activities and financial results. Ipsen cannot be\ncertain that its partners will fulfil their obligations. It might be unable to\nobtain any benefit from those agreements. A default by any of Ipsen’s\npartners could generate lower revenues than expected. Such situations could\nhave a negative impact on Ipsen’s business, financial position or\nperformance. Ipsen expressly disclaims any obligation or undertaking to update\nor revise any forward-looking statements, targets or estimates contained in\nthis press release to reflect any change in events, conditions, assumptions or\ncircumstances on which any such statements are based, unless so required by\napplicable law. Ipsen’s business is subject to the risk factors outlined in\nits registration documents filed with the French Autorité des Marchés\nFinanciers. The risks and uncertainties set out are not exhaustive and the\nreader is advised to refer to Ipsen’s latest Universal Registration\nDocument, available on ipsen.com\n(https://www.globenewswire.com/Tracker?data=BbAZ2BLSbvGq6xmtVoi1-hAjOoFiYcsDh6llWdBa9bRjUv9MdVeZez5C0cE8qnlBbsB6vPlGAqEMua2vQjpIfw==).\n\nAttachment\n*     Ipsen PR_Acquisition of Kartos Therapeutics_21082026\n(https://ml-eu.globenewswire.com/Resource/Download/90ca8d16-d012-44b9-bf9d-9796cbcd49a7)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/81292fcc-6b3a-4e4a-a083-ea4191bf920a)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX2P6HGj","title":"Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline","author":"Globe Newswire","ticker":"IPN","created":"2026-08-21T05:00:00.359Z","tickers":["IPN"],"exchange":"Euronext Paris","article_body":"PARIS, FRANCE, 21 AUGUST 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced\ntoday it has completed the acquisition of Kartos Therapeutics, a\nclinical-stage biopharmaceutical company adding late-stage MDM2 inhibitor\nnavtemadlin in Phase III clinical development in myelofibrosis.\n\nAbout navtemadlin\nNavtemadlin is an investigational oral MDM2 inhibitor being developed as an\nadd-on therapy to ruxolitinib for patients with myelofibrosis who have a\nsuboptimal response to ruxolitinib. The Phase III POIESIS study is evaluating\nwhether the addition of navtemadlin could improve clinical outcomes compared\nwith ruxolitinib alone in this patient population. Early clinical data\ndemonstrate navtemadlin has the potential to transform suboptimal responses to\nstandard of care ruxolitinib into clinically meaningful responses in patients\nwith intermediate and high risk TP53wt myelofibrosis, to provide both enhanced\nclinical outcomes and potential disease-modifying benefit.\n\nAbout myelofibrosis\nMyelofibrosis is a myeloproliferative neoplasm, frequently linked to\nalterations in the JAK/STAT pathway, in which patients develop bone marrow\nfibrosis due to the abnormal proliferation of hematopoietic stem cells and\nsecretion of fibrogenic cytokines. As marrow function declines, blood\nproduction shifts to other organs, most often the spleen, leading to\nsplenomegaly. Myelofibrosis is characterized by bone marrow failure, fibrosis,\nsplenomegaly and a high symptom burden that can significantly affect quality\nof life, including fatigue, night sweats and other progressive symptoms. It\nalso carries a risk of transformation to acute myeloid leukemia. The median\nage at diagnosis is approximately 67–69 years and the condition affects\naround 1.5 per 100,000 people in the U.S. and Europe. Approximately 75–89%\nof patients are intermediate- or high-risk at diagnosis and more than 95% are\nTP53wt. Ruxolitinib, a JAK inhibitor, is the first-line standard of care;\nhowever, it is estimated that a significant proportion of patients have an\ninitial suboptimal response and approximately 50%-75% discontinue treatment\nafter three years. Median overall survival is typically one to two years after\ntreatment discontinuation, underscoring the need for new strategies that can\nincrease the number of patients that can achieve optimal clinical outcomes.\n\nAbout Ipsen\nWe are a global biopharmaceutical company with a focus on bringing\ntransformative medicines to patients in three therapeutic areas: Oncology,\nRare Disease and Neuroscience. Our pipeline is fueled by internal and external\ninnovation and supported by nearly 100 years of development experience and\nglobal hubs in the U.S., France and the U.K. Our teams in more than 40\ncountries and our partnerships around the world enable us to bring medicines\nto patients in more than 100 countries.\n\nIpsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored\nLevel I American Depositary Receipt program (ADR: IPSEY). For more\ninformation, visit ipsen.com\n(https://www.globenewswire.com/Tracker?data=BbAZ2BLSbvGq6xmtVoi1-iGZTycFlW2vubdYjMJ4Bfl7W3zruifxm8x1raxkR2Ko-4GUVOY8qt1OWiWlqPJqtA==).\n\n Ipsen Contacts                                                 \n Investors                                                      \n Henry Wheeler   henry.wheeler@ipsen.com     +33 7 66 47 11 49  \n Khalid Deojee   khalid.deojee@ipsen.com     +33 6 66 01 95 26  \n                                                                \n Media                                                          \n Sally Bain      sally.bain@ipsen.com        +1 857 320 0517    \n Anne Liontas    anne.liontas.ext@ipsen.com  +33 7 67 34 72 96  \n                                                                \n\nDisclaimers and/or forward-looking statements\nThe forward-looking statements, objectives and targets contained herein are\nbased on Ipsen’s management strategy, current views and assumptions. Such\nstatements involve known and unknown risks and uncertainties that may cause\nactual results, performance or events to differ materially from those\nanticipated herein. All of the above risks could affect Ipsen’s future\nability to achieve its financial targets, which were set assuming reasonable\nmacroeconomic conditions based on the information available today. Use of the\nwords ‘believes’, ‘anticipates’ and ‘expects’ and similar\nexpressions are intended to identify forward-looking statements, including\nIpsen’s expectations regarding future events, including regulatory filings\nand determinations. Moreover, the targets described in this document were\nprepared without taking into account external-growth assumptions and potential\nfuture acquisitions, which may alter these parameters. These objectives are\nbased on data and assumptions regarded as reasonable by Ipsen. These targets\ndepend on conditions or facts likely to happen in the future, and not\nexclusively on historical data. Actual results may depart significantly from\nthese targets given the occurrence of certain risks and uncertainties, notably\nthe fact that a promising medicine in early development phase or clinical\ntrial may end up never being launched on the market or reaching its commercial\ntargets, notably for regulatory or competition reasons. Ipsen must face or\nmight face competition from generic medicine that might translate into a loss\nof market share. Furthermore, the research and development process involves\nseveral stages each of which involves the substantial risk that Ipsen may fail\nto achieve its objectives and be forced to abandon its efforts with regards to\na medicine in which it has invested significant sums. Therefore, Ipsen cannot\nbe certain that favorable results obtained during preclinical trials will be\nconfirmed subsequently during clinical trials, or that the results of clinical\ntrials will be sufficient to demonstrate the safe and effective nature of the\nmedicine concerned. There can be no guarantees a medicine will receive the\nnecessary regulatory approvals or that the medicine will prove to be\ncommercially successful. If underlying assumptions prove inaccurate or risks\nor uncertainties materialize, actual results may differ materially from those\nset forth in the forward-looking statements. Other risks and uncertainties\ninclude but are not limited to, general industry conditions and competition;\ngeneral economic factors, including interest rate and currency exchange rate\nfluctuations; the impact of pharmaceutical industry regulation and healthcare\nlegislation and risks arising from unexpected regulatory or political changes\nsuch as changes in tax regulation and regulations on trade and tariffs, such\nas protectionist measures, especially in the United States; global trends\ntoward healthcare cost containment; technological advances, new medicine and\npatents attained by competitors; challenges inherent in new-medicine\ndevelopment, including obtaining regulatory approval; Ipsen’s ability to\naccurately predict future market conditions; manufacturing difficulties or\ndelays; financial instability of international economies and sovereign risk;\ndependence on the effectiveness of Ipsen’s patents and other protections for\ninnovative medicines; and the exposure to litigation, including patent\nlitigation, and/or regulatory actions. Ipsen also depends on third parties to\ndevelop and market some of its medicines which could potentially generate\nsubstantial royalties; these partners could behave in such ways which could\ncause damage to Ipsen’s activities and financial results. Ipsen cannot be\ncertain that its partners will fulfil their obligations. It might be unable to\nobtain any benefit from those agreements. A default by any of Ipsen’s\npartners could generate lower revenues than expected. Such situations could\nhave a negative impact on Ipsen’s business, financial position or\nperformance. Ipsen expressly disclaims any obligation or undertaking to update\nor revise any forward-looking statements, targets or estimates contained in\nthis press release to reflect any change in events, conditions, assumptions or\ncircumstances on which any such statements are based, unless so required by\napplicable law. Ipsen’s business is subject to the risk factors outlined in\nits registration documents filed with the French Autorité des Marchés\nFinanciers. The risks and uncertainties set out are not exhaustive and the\nreader is advised to refer to Ipsen’s latest Universal Registration\nDocument, available on ipsen.com\n(https://www.globenewswire.com/Tracker?data=BbAZ2BLSbvGq6xmtVoi1-hAjOoFiYcsDh6llWdBa9bRjUv9MdVeZez5C0cE8qnlBbsB6vPlGAqEMua2vQjpIfw==).\n\nAttachment\n*     Ipsen PR_Acquisition of Kartos Therapeutics_21082026\n(https://ml-eu.globenewswire.com/Resource/Download/90ca8d16-d012-44b9-bf9d-9796cbcd49a7)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/81292fcc-6b3a-4e4a-a083-ea4191bf920a)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-08-21T05:00:00.426162427Z","server_sent_at_ms":1787288400426},"received_at":"2026-08-21T05:00:00.476Z","source_url":null},"analysis":{"id":"113596","press_release_id":"124626","analysis_json":{"industry":{"label":"Pharmaceuticals","sector":"Health Care"},"redFlags":[],"eventType":"m_and_a","narrative":"Ipsen has finalized the acquisition of Kartos Therapeutics, adding navtemadlin, a late-stage MDM2 inhibitor, to its oncology pipeline.\n\nThe drug is currently in Phase III development as an add-on therapy for myelofibrosis patients who have a suboptimal response to ruxolitinib.\n\nThe POIESIS study targets intermediate and high-risk TP53 wild-type patients, aiming to improve clinical outcomes where current standard of care often fails.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Ipsen bolsters oncology pipeline with closing of Kartos acquisition, securing Phase III navtemadlin."},"keyFigures":{"drugName":"navtemadlin","phaseOfTrial":"Phase III","customDimensions":{"prevalence":"1.5 per 100,000","tp53wt_prevalence":">95%","discontinuation_rate":"50%-75%"}},"quotedText":"","namedEntities":{"people":[],"products":["navtemadlin","ruxolitinib"],"companies":[{"name":"Ipsen","ticker":"IPN"},{"name":"Kartos Therapeutics","relationship":"acquiree"}],"dollarAmounts":[]},"materialImpact":{"score":4,"reasoning":"Acquisition of a Phase III asset represents a significant pipeline expansion for Ipsen. While the deal value is undisclosed, securing navtemadlin adds potential late-stage revenue in the high-unmet-need myelofibrosis market."},"tickerRelevance":{"others":[{"ticker":"IPSEY","relevance":"ADR"}],"primary":"IPN"},"globalImportance":35,"audienceRelevance":30,"eventTypeSecondary":["clinical_trial"],"importanceComponents":{"tickerTier":"large-cap","eventGravity":"m_and_a_closing","sectorWeight":"biotech_pharma"}},"event_type":"m_and_a","event_type_secondary":["clinical_trial"],"sentiment":"bullish","material_impact_score":4,"narrative":"Ipsen has finalized the acquisition of Kartos Therapeutics, adding navtemadlin, a late-stage MDM2 inhibitor, to its oncology pipeline.\n\nThe drug is currently in Phase III development as an add-on therapy for myelofibrosis patients who have a suboptimal response to ruxolitinib.\n\nThe POIESIS study targets intermediate and high-risk TP53 wild-type patients, aiming to improve clinical outcomes where current standard of care often fails.","key_figures":{"drugName":"navtemadlin","phaseOfTrial":"Phase III","customDimensions":{"prevalence":"1.5 per 100,000","tp53wt_prevalence":">95%","discontinuation_rate":"50%-75%"}},"named_entities":{"people":[],"products":["navtemadlin","ruxolitinib"],"companies":[{"name":"Ipsen","ticker":"IPN"},{"name":"Kartos Therapeutics","relationship":"acquiree"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-21T05:04:10.691Z","global_importance":35,"audience_relevance":30,"importance_components":{"tickerTier":"large-cap","eventGravity":"m_and_a_closing","sectorWeight":"biotech_pharma"}},"durationMs":122683,"modelName":"glm-4.7"}}